Oral Agents for Cancer-Related VTE: ' New Standard of Care ' Oral Agents for Cancer-Related VTE: ' New Standard of Care '

The oral agent rivaroxaban was as effective as subcutaneous dalteparin in controlling VTE in patients with cancer but was associated with a higher rate of bleeding.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news